Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Parallel-designed Clinical Study to Evaluate the Efficacy and Safety of HL-1186 in Patients With Diabetic Peripheral Neuropathic Pain

NCT07159243 is registered in ClinicalTrials.gov with Shanghai Yidian Pharmaceutical Technology Development Co., Ltd. as lead sponsor.

NCT NCT07159243
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07159243 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Parallel-designed Clinical Study to Evaluate the Efficacy and Safety of HL-1186 in Patients With Diabetic Peripheral Neuropathic Pain
Lead sponsor
Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.
Phase
Phase 2
Overall status
Not yet recruiting
Start date
September 30, 2025
Completion date
October 31, 2026
Enrollment
180 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

diabetic peripheral neuropathic pain